Member Info for crumbs

The closest we got to an ImmunoBody flu vaccine https://immbio.net/uploads/documents/Poster_Fusion_Proteins_FluBioVax.pdf

On this as has been written it is not an area scancell themselves are currently able to take ImmunoBody forwards in and no collaborator took it forwards either but I wonder does the moving away from electroporation (Ichor) delivery to nano delivery make it a more attractive platform to any player who would like to take it on to tackle viruses.... I'm not expecting anything in that area myself though yeah the whole coronavirus situation makes it topical plus our old mates Inovio are very active in this area and managed to get some serious wonga off Bill Gates no less .

Back in September 2019, this is where scancell were with their TCR program that had suffered a 6-month delay to the planned original timeline due to waiting for a Health and Safety approval which was approved:
'Lenti-viral transduction of T cells now working in the lab
40 TCRs recognising citrullinated/homocitrullinated epitopes to screen '
It is interesting that the TCR deal with BioNTech is for the use of modi1 only yet obviously modi2 is also being used.
Anyways I wonder where they are up to now!

Seems to have upset certain parties......why? Hmmm

The part-timer slur has been used before and it is beneath contempt.... The IP of scancell is Lindy's lifeswork... now the glycans and avidimab are here too and the student pivotal to their development a Notts uni student is a full time scancell employee.... Scancell have gained hugely from Lindys professorship at Notts plus all the grants she has been given and access to students.... The costs if she were not would be huge!....

'priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer'
https://www.roche.com/media/releases/med-cor-2020-02-19.htm

And although the lack of any visible progress from CRUK with SCIB2 beyond their support of and acceptance of nano delivery...We should not forget so much of Lindy's work... the work which makes up scancells IP has been funded by CRUK....

Agree with all that C7... though I still hold out hope modi1 will get into trial later this year as it does seem the only hurdle there is the last piece of that rather complicated manufacturing puzzle which I have faith in them putting into place... Scancell does have faithful ii's in Calculus, OXT, Hygea and now all the indicators are Vulpes too.... Hopefully, Cliff got some US interest from the specialist funds over there as that would be a great boost

I don't know if has or not already but DE would be the one who could offer the greatest insight into BOD share buying or not buying of shares....He himself always dug the deepest and has since leaving the BOD too I would think 'personal circumstances' do play a major part but there may be other things too.... The tech here is Lindy's lifes work and if they prove successful or even half as successful as their potential she will end up very very wealthy I never get the feeling she is here for the money though... but is not behind the door where it is concerned :) ..... A rec for your post off me Ivy and understand Mitch's position and best wishes to him too...

Yeah, I think that is the case too and once one does watch the others come as it really seems there is a herd mentality when it comes to yet to be proved but potentially game-changing techs no one likes to take the risk but once one does no one wants to not take the risk lol... Obviously we hope they nail that TCR deal and Glycan/Avidimab deals this year ...All we know is those collaborations with that end are indeed here so it is a wait and see but the odds are better than ever before

I forgot CRUK which is also a collaboration with a potential commercial outcome...
So 6 potential commercial outcomes all with many potential Cancer Targets ... Also I do not dismiss the possibility of modi 1 still gaining a partner once the final manufacturing hurdle has been jumped... Cliff tells me they are in constant talks about all techs all the time... yeah he would say that ....But when project Blueprint appeared and you saw the list of people Lindy had managed to attract to work under her leadership and you realise wow this is not as under the radar as we once thought, at least not in the Immuno oncology circles that matter.

DE bought a million after the Vulpes coming in news ...He holds them in the highest regards and did try in his time to get them invested....This is not VAL a BOD lifestyle vechile of disgarded techs brought in and 'pimped up' (their own words) then the whole risk of that going nowhere (as it has) offloaded onto gullible investors some of whom are amazingly still buying it!!!!! No scancell all in house totally novel techs enough PHD's on team scancell science to rival the likes of BioNTech and others the very fact modi1 is a pioneering never before produced product goes to just show how cutting edge the science is here and means the IP will not be able to be just copied and knocked out by anyone wanting to make copies of .....Different class... yet to be rewarded....but those collaborations are here if we add in TCR we have 4 collaborations all potentially ending with commercial deal/s ...Try before you buy or in TCR's case gain huge knowhow and possibly end up with a none IP dilutive validating commercial deal.

Vulpes recently took a chunk off the market and a few of us pi still buying

Yeah... All I can say is Cliff to me seemed quite confident on their being a 'transactions later this year' The fact 3 collaborators have come in rather fast shows the interest is real and not made up and like I say fact these techs have such broad application potential and that whoever these collaborators are are capable at looking at the techs in all those applications shows they must be rather capable collaborators as that is a lot of complicated lab work

His £4 million is not going to last long lol

I also say if the collaborators are looking at the Glycans/Avidimab in 'ICD ADC CAR-T Bispecifics and In vivo and In vitro
TSCM expansion' Then they must be quite serious outfits

Ain't that the truth!.... Though to be fair here we are only going to have that opportunity on commercial deal/s and clinical success which at least on the commercial deal/s front we have not had so all the play for....
The deal potential on Glycan Mabs/AvidiMab ... is acctually rather massive when you look at the TaG summary and listen to Cliffs words at the LSX presentation.... 5 Mabs... over 6 potential cancer targets multiple a broad range of applicability... i.e can be used in CAR T,bispecifics (hot areas) plus AvidiMab has potential to improve any MaB (massive potential that if proves true) All the collaborators are according to Cliff looking at both the MaBs and Avidimab in those multiple possible apllications.... So the number of potential deals on them could be rather huge.... the first would be nice though and get that ball rolling :) ...

And 33p.... really wasn't :)

3.6.... really was !

The other 'core platforms' well apart from modi1 with TCRs (which was mentioned and BiONtech obviously still on the scene)do not have 'collaborations' ...We know the plan with Glycans/AvidiMab and that is to get early stage cash up front deals on them to fund the core techs through data-producing and therefore much more value-adding potential to any future deals on those....And that plan seems to be going to work out... 3 collaborations already looking at both the 5 Glycans and AvidiMab... potential of plenty of cash upfront deals there especially seeing as those 5 Glycan Mabs have multiple targets so could possibly be target by target deals... Anyways we will see... And modi 1 trial planning is taking clearer shape too with it being 4 trials in one... Again a derisking.... nothing to be negative about apart from the first cash upfront deal/s have not arrived yet.. but is that not the time to be buying in here? unless you have no faith at all then why be here at all lol